Benjamin P. Levy, MD, discusses the evolution of molecular drivers in non–small cell lung cancer over the last few years and which testing should be included in patients.
Benjamin P. Levy, MD, clinical director of medical oncology and associate professor of oncology at Johns Hopkins Sidney Kimmel Cancer Center in Sibley Memorial Hospital, Washington, DC, discusses the evolution of molecular drivers in nonsmall cell lung cancer (NSCLC) over the last few years and which testing should be included in patients with NSCLC.
Levy says research has come a long way in terms of the molecular driver identification in NSCLC. Initially, it started with testing forEGFRandALKin patients with advanced adenocarcinoma of the lung, but now there are a number of mutations that we can test for, including RET, ROS1, BRAF, HER2, METexon 14 skipping, NTRK,andKRAS.If these mutations are identified, patients can be treated with a targeted therapy that has been approved by the FDA or is under the umbrella of a clinical trial.
The list continues to grow in terms of actionable mutations that should be tested for, Levy says. He says this is a call for comprehensive genomic profiling for lung cancer. More testing should be done outside of sequentialEGFR, ALK, ROS1,andBRAF. Larger panels can be used to identify all of the mutations necessary at this time to improve outcomes for patients with NSCLC harboring 1 of these mutations.
For more from Levy's interview withTargeted Oncology:
https://www.targetedonc.com/conference/nylung-2019/expert-reviews-evolving-treatment-standards-for-nondriver-and-molecularly-driven-nsclc
KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC
November 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More